No Reliable Screening Test Exists for Ovarian Cancer — the Silent Killer

Ovarian cancer is the deadliest gynecological cancer because there is no effective screening test. CA-125 blood test and transvaginal ultrasound have been tested extensively but failed to reduce mortality in large RCTs. 70%+ of cases are diagnosed at Stage III/IV where 5-year survival is only 30%.

CA-125 is elevated in only ~50% of Stage I ovarian cancers and is also elevated in endometriosis, fibroids, and pregnancy. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, 200,000 women, 20 years) showed that multimodal screening (CA-125 + ROCA algorithm + ultrasound) did not significantly reduce ovarian cancer deaths vs no screening. HE4 adds some specificity but doesn't solve the sensitivity problem. ctDNA and methylation-based approaches are being explored but face the challenge of very low tumor DNA shedding from early-stage ovarian tumors.

Why It Matters

~20,000 new US cases/year, ~13,000 deaths. Stage I 5-year survival: 93%. Stage III/IV: 30%. Early detection would save ~8,000+ lives/year in the US. The UKCTOCS result was a devastating blow to the field — the most rigorous screening trial ever conducted showed no mortality benefit.

Startup Approach

Develop a multi-omic screening approach combining DNA methylation, protein biomarker panels, and metabolomics specifically optimized for ovarian cancer detection in high-risk populations (BRCA1/2 carriers, Lynch syndrome). Or develop ultra-sensitive ctDNA detection specifically tuned for the low tumor fraction seen in early ovarian cancer.

NIH Funding

NCI EDRN funds ovarian cancer biomarker research. NCI's Division of Cancer Prevention supports screening studies.

Who's Working On It

Aspira Women's Health (OVA1/Overa), GRAIL (Galleri includes ovarian), NCI EDRN ovarian cancer biomarker programs, Johns Hopkins (SPOT-MAS multi-cancer detection)